The COVID-19 pandemic may have shocked most of the world, but in ways, Richard Beigi saw it coming.

Beigi, president of UPMC Magee-Womens Hospital and a reproductive infectious disease researcher, has spent the past 10-plus years working to find safe and effective ways to include pregnant women in vaccine development studies, knowing they’re more susceptible to the devastating effects of the viruses vaccines seek to tame.

The initial COVID-19 vaccine trials didn’t reflect those calls for change, but the exclusion ignited a thought that led to the recent publication of a study that answers two important, lingering questions concerning the impact of COVID-19 vaccinations on the unborn.

“Because they were under-studied, myself and a few other colleagues who had been doing research in this space said, ‘If we can’t get the pregnant women in the study from the outset, we should study them now that the vaccine is being given,’” he said. “It was our idea to capitalize on the fact that, even though we didn’t have data from when the first studies were done, we knew some women were taking the vaccine, so let’s study them.”

Advertise with us

Known as the MOMI-Vax Study Group, Beigi, fellow UPMC Magee obstetrician Katherine Bunge and others are doing exactly that.

In June, they concluded that “robust immune responses” created in pregnant women after both doses of the COVID-19 vaccine, and more so after a booster during pregnancy, did indeed transfer to their babies — a confirmation provided by the presence of COVID-19 antibodies in umbilical cord blood of newborn study participants after birth.

But that knowledge lacked two important components: Was that passive immunity enough to actually prevent disease, and how long would it last in those babies after birth?

Beigi and his team have since answered those questions.

Published in the journal Pediatrics earlier this month, the group’s newest work showed that pregnant women who received two doses of the COVID-19 vaccine — and especially the group that also received a booster — not only passed the resultant antibodies to their babies effectively enough to prevent disease, but that protection lasted six months, which covers the infants until they’re eligible for their own COVID-19 vaccines at 6 months old.

Advertise with us

This comes just after the Center for Disease Control and Prevention released its most recent data — from the week of Jan. 27 — showing that just 12.5% of the current pregnant population, ages 18 to 49, received the 2023-24 COVID-19 booster.

“It’s very helpful from a provider’s perspective to have published data, and not just, I think this and I think that,” Beigi said. “It’s not just an idea. We have data that proves it.”

Beginning in 2021, mom-baby dyads were selected from nine academic sites in the U.S., including Magee-Womens Hospital, for the MOMI-Vax investigations. The recently published study included 475 of those duos, with just over 200 having received the two-dose COVID-19 vaccine and a booster, and just over 270 who were un-boosted.

In total, 90 cases of COVID-19 were confirmed among the infants in the first six months after birth. Since the omicron variant’s appearance in 2022, this youngest group of patients is hospitalized at a rate on par with another high-risk group, adults ages 65 to 74 years old. But in the study, none of the 90 cases of COVID resulted in hospitalization.

Infants born to boosted mothers had significantly higher increases in COVID-aimed immune system mediators compared to non-boosted mothers, and were 56% less likely to acquire the virus within the first six months.

Advertise with us

There did seem to be an optimal time for mothers to receive that booster, however.

One immune mediator, Spike IgG, measured in the neonate at delivery, was lowest — but not zero — when mom was boosted during the first trimester, or the first 13 weeks of pregnancy. The levels increased with each week of gestation when boosted during the second trimester, or up until 26 weeks. But Spike IgG … spiked … when mothers were boosted between 28 and 34 weeks, with a slight decline in levels when boosted after about 34 weeks.

But pregnant women shouldn’t start counting their weeks and making booster appointments just yet: These data were gathered in 2021, which was a much different COVID-era landscape.

“Now, we’re talking about seasonal immunization, whereas before, we were talking about just getting the vaccine as fast as you can,” Beigi said.

Said another way, an obstetrics practitioner will not automatically recommend boosters for patients — let alone at a particular point in pregnancy — based only on these findings. Beigi predicts practitioner-patient collaborations, which take many factors into account, such as current COVID vaccine status, when the last one occurred, health status of the mother and baby, and time of year, among others.

Advertise with us

This study isn’t the last time the world will hear from the MOMI-Vax group, as Beigi says they’ll draw more conclusions and publish more work based on this cohort of moms and babies.

Before these data, many obstetric practitioners felt confident that COVID-19 vaccines would be safe and effective for moms and babies based on previous vaccine data showing the same.

Now, MOMI-Vax data could serve the same purpose in the future, and may contribute to Beigi’s ultimate research goal of including one of the most vulnerable groups to infectious diseases, pregnant women, in vaccine development studies.

“There’s always a risk of harm no matter what you’re taking,” Beigi said. “But there’s also a risk to not studying it because then you have a population who’s uniquely susceptible to outcomes, who’s then reluctant to take the vaccine because there’s no data. It’s not a no-risk situation, partly because there’s a risk to not studying this group.”

Abby Mackey is a registered nurse and can be reached at amackey@post-gazette.com and IG @abbymackeywrites